|
|
|
|
|
|
|
|
|
16.12.25 - 09:06
|
LEO Pharma Appoints Marika Murto to Lead Global Product Strategy (Business Wire)
|
|
|
Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation
Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma's portfolio potential, driving patient impact and supporting sustainable growth
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, announces the appointment of Marika Murto, PhD, as SVP of Global Product Strategy and member of the Global Leadership Team.
Marika joins LEO Pharma from Amgen, where she most recently served as Associate Vice President and U.S. Commercial Lead for Bone Health, driving strategic brand positioning and cross‑functional collaboration. Her career at Amgen included senior global and affiliate leadership roles, including General Manager for the Netherlands, Global Product Team Lead for Bone Health, and Country Director for Finland. She has also held senior commercial positions at Pfizer and Roche, gaining expertise across oncology, vaccines, speci...
|
|
|
16.12.25 - 07:42
|
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director (Business Wire)
|
|
|
OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that Gijs van den Brink, MD, PhD, has been appointed as an independent director to the company's Board of Directors. Dr. van den Brink is a highly accomplished researcher and drug developer, having led immunology research and clinical development at both Roche and GSK.
“Gijs brings an exceptional blend of scientific depth, clinical insight, and strategic leadership to our board of directors,” said Calluna CEO Mark Gaffney. “We are thrilled to welcome him and are confident his expertise will strengthen our mission as we advance our pipeline in fibrotic and other inflammatory disorders.”
Dr. van den Brink had a distinguished tenure at Roche, where he served on the Pharma Research and Early Development (pRED) leadership team and was SVP and Global Head of Immunology, CVM, Infectious Diseases, and Ophthalmol...
|
|
|
|
|
|
|
15.12.25 - 11:00
|
Roche Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche mit einem Kursziel von 325 Franken auf "Hold" belassen. Die Schweizer hätten in ihrer Telefonkonferenz anlässlich des San Antonio Breast Cancer Symposium (SABCS) ein deutlich ......
|
|
|
12.12.25 - 13:27
|
Roche Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche mit einem Kursziel von 325 Franken auf "Hold" belassen. Die positive Kursreaktion auf Studiendaten zu einer neuen Hormontherapie der Schweizer bei Brustkrebs sei aus seiner ......
|
|
|
|
|
|
|
|
|
11.12.25 - 12:30
|
Roche Sell (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Roche mit einem Kursziel von 260 Franken auf "Sell" belassen. Die Details der Giredestrant-Brustkrebsstudie lidERA seien solide, schrieb James Quigley am Donnerstag. ......
|
|
|
11.12.25 - 10:45
|
Roche Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Roche von 314 auf 356 Franken angehoben und die Einstufung auf "Buy" belassen. Die detaillierten Daten der Giredestrant-Brustkrebsstudie seien stark ausgefallen, schrieb Matthew ......
|
|
|
11.12.25 - 08:06
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche mit einem Kursziel von 350 Franken auf "Neutral" belassen. Detaillierte Daten aus einer Brustkrebsstudie zu Giredestrant untermauerten das Umsatzpotenzial des Krebsmittels ......
|
|
|
11.12.25 - 08:06
|
Roche Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Roche mit einem Kursziel von 230 Franken auf "Underperform" belassen. Die detaillierten Daten der Giredestrant-Brustkrebsstudie ließen einige Fragen offen, schrieb Michael ......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
